RSPO3 and neoplasm: In a more recent trial with porcupine inhibitors, preliminary results show that patients with CRC that harbor RSPO3 fusions, which renders tumor growth dependent on Wnt ligands, might benefit from a combination of porcupine inhibition and immune checkpoint blockade.550 DKK1 is an antagonist of the Wnt pathway that can be targeted by the antibody DKN-01.